Efforts on the therapeutic management of pediatric ALL through epigenetic drugs are already well documented [58], and HDAC inhibitors have been incorporated in combination strategies with various drug categories for the treatment of cancer at preclinical or clinical stages [59,60]. Here, HDAC9 is linked to cancer.